# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
JMP Securities analyst Jason Butler reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and maintains $...
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate o...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthca...
JMP Securities analyst Jason Butler reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and maintains $...
Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic rea...